Why Biogen's New CEO Stands To Gain From An Acquisition
Biogen’s announcement Monday that chief commercial officer Michel Vounatsos will take over as CEO has rekindled a debate over whether the Cambridge biotech could be acquired in its current, precarious state.
But at least one thing is clear: Vounatsos stands to personally benefit if Biogen (Nasdaq: BIIB) is purchased.
A look at Vounatsos' employment agreement, which was posted in a regulatory filing late Monday, shows that Biogen is giving its new chief generous protections in the event of a “change of control” — corporate-speak for an acquisition.
But at least one thing is clear: Vounatsos stands to personally benefit if Biogen (Nasdaq: BIIB) is purchased.
A look at Vounatsos' employment agreement, which was posted in a regulatory filing late Monday, shows that Biogen is giving its new chief generous protections in the event of a “change of control” — corporate-speak for an acquisition.